This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Journal: Neurocase 1-7(2012)
Authors: :F.S Bersani, N Girardi, L Sanna, L Mazzarini, C Santucci, G.D Kotzalidis, G Sani, P De Rossi, R.N Raccah, S.S Caltagirone, M Battipaglia, S Capezzuto, G Bersani, P Girardi
Deep Transcranial Magnetic Stimulation (dTMS) is currently being evaluated as a possible treatment for several neuropsychiatric disorders and has been demonstrated as a safe and effective procedure.
This report aimed to assess efficacy and safety of daily add-on dTMS in relieving drug-resistant bipolar depression, and its ability to protect from episodes of either polarity during a 3-month maintenance period, with fortnightly sessions, and during another 3-month period, with no dTMS sessions and only continuation drug treatment.
This case presents a patient with bipolar depression that has been treated with 20 daily consecutive dTMS sessions and with one dTMS session every 2 weeks for the following 3 months.
Depressive symptoms improved rapidly and response was maintainedduring the next 6 months. Cognitive performances also improved.
This report suggests that add-on dTMS may help overcoming drug-resistance in bipolar depression and protect from subsequent bipolar episodes of any polarity.